Table 5.
Logistic regression analysis of clinicopathological factors and pathological complete response after neoadjuvant chemotherapy in breast cancer
| Factors | Multivariate analysis | ||
|---|---|---|---|
| OR | 95% CI | P value | |
| TT (continuous) | – | – | 0.881 |
| Fib status (low vs high) | 3.038 | 1.667–5.537 | < 0.001 |
| Tumour size (≤ 5 cm vs > 5 cm) | 3.052 | 1.484–6.276 | 0.002 |
| Lymph node involvement (no vs yes) | 2.840 | 1.863–4.328 | < 0.001 |
| Subtype | |||
| HR (+) HER2 (−) | 1 | Ref. | Ref. |
| HR (+) HER2 (+) | 1.594 | 0.858–2.961 | 0.140 |
| HR (−) HER2 (+) | 2.410 | 1.348–4.307 | 0.003 |
| HR (−) HER2 (−) | 2.954 | 1.597–5.464 | 0.001 |
| Ki67 index (> 14% vs ≤ 14%) | 3.163 | 1.633–6.125 | 0.001 |
| Chemotherapy cycles (≥ 4 vs < 4) | – | – | 0.679 |
Abbreviations: CI confidence interval, OR odds ratio, TT thrombin time, Fib fibrinogen, HR hormone receptor, HER2 human epidermal growth factor receptor 2